| Identification | Back Directory | [Name]
2-Thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl-, compd. with 4-methylbenzenesulfonate (1:1) | [CAS]
2649012-17-7 | [Synonyms]
Crinecerfont PTSA salt
2-Thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl-, compd. with 4-methylbenzenesulfonate (1:1) | [Molecular Formula]
C27H28ClFN2OS.C7H8O3S | [Molecular Weight]
655.25 |
| Hazard Information | Back Directory | [Uses]
Crinecerfont tosylate is an effective orally active antagonist of the CRF1 receptor. Crinecerfont tosylate can be used in research on congenital adrenal hyperplasia (CAH)[1]. | [References]
[1] Newfield R S, et al. Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia[J]. The Journal of Clinical Endocrinology & Metabolism, 2023, 108(11): 2871-2878. DOI:10.1210/clinem/dgad270 |
|
|